Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Yeung

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Frontiers in Aging Neuroscience|April 4, 2022
COVCOG 1: Factors Predicting Physical, Neurological and Cognitive Symptoms in Long COVID in a Community Sample. A First Publication From the COVID and Cognition StudyPanyuan Guo, Alvaro Benito Ballesteros, Sabine P Yeung, et al.
Journal of Child and Adolescent Psychopharmacology|July 12, 2023
Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability StudyPaul P Yeung, Kimball A Johnson, Robert Riesenberg, et al.
Headache|April 23, 2021
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM studyRichard B Lipton, Joshua M Cohen, Maja Galic, et al.
Cephalalgia : an International Journal of Headache|April 19, 2018
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjectsOrit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 27, 2004
Quetiapine improves psychotic symptoms and cognition in Parkinson's diseaseJorge L Juncos, Vicki J Roberts, Marian L Evatt, et al.
The New England Journal of Medicine|November 25, 2017
Fremanezumab for the Preventive Treatment of Chronic MigraineStephen D Silberstein, David W Dodick, Marcelo E Bigal, et al.
JAMA|May 26, 2018
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical TrialDavid W Dodick, Stephen D Silberstein, Marcelo E Bigal, et al.
New Zealand Veterinary Journal|February 12, 2025
Investigating animals and environments in contact with leptospirosis patients in Aotearoa New Zealand reveals complex exposure pathwaysJ Benschop, J M Collins-Emerson, E Vallee, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 24, 2005
Inter-relationships between DNA damage, ascorbic acid and glycaemic control in Type 2 diabetes mellitusS W Choi, I F F Benzie, C S Y Lam, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 10, 2016
A multicentre demonstration project to evaluate the effectiveness and acceptability of the web-based Joint Asia Diabetes Evaluation (JADE) programme with or without nurse support in Chinese patients with Type 2 diabetesG E Tutino, W Y Yang, X Li, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Frontiers in Aging Neuroscience|April 4, 2022
COVCOG 1: Factors Predicting Physical, Neurological and Cognitive Symptoms in Long COVID in a Community Sample. A First Publication From the COVID and Cognition StudyPanyuan Guo, Alvaro Benito Ballesteros, Sabine P Yeung, et al.
Journal of Child and Adolescent Psychopharmacology|July 12, 2023
Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability StudyPaul P Yeung, Kimball A Johnson, Robert Riesenberg, et al.
Headache|April 23, 2021
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM studyRichard B Lipton, Joshua M Cohen, Maja Galic, et al.
Cephalalgia : an International Journal of Headache|April 19, 2018
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjectsOrit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 27, 2004
Quetiapine improves psychotic symptoms and cognition in Parkinson's diseaseJorge L Juncos, Vicki J Roberts, Marian L Evatt, et al.
The New England Journal of Medicine|November 25, 2017
Fremanezumab for the Preventive Treatment of Chronic MigraineStephen D Silberstein, David W Dodick, Marcelo E Bigal, et al.
JAMA|May 26, 2018
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical TrialDavid W Dodick, Stephen D Silberstein, Marcelo E Bigal, et al.
New Zealand Veterinary Journal|February 12, 2025
Investigating animals and environments in contact with leptospirosis patients in Aotearoa New Zealand reveals complex exposure pathwaysJ Benschop, J M Collins-Emerson, E Vallee, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 24, 2005
Inter-relationships between DNA damage, ascorbic acid and glycaemic control in Type 2 diabetes mellitusS W Choi, I F F Benzie, C S Y Lam, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 10, 2016
A multicentre demonstration project to evaluate the effectiveness and acceptability of the web-based Joint Asia Diabetes Evaluation (JADE) programme with or without nurse support in Chinese patients with Type 2 diabetesG E Tutino, W Y Yang, X Li, et al.
Pageof 9